Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Shares of Emergent Biosolutions Inc. (NYSE:EBS) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.65 and traded as high as $12.58. Emergent Biosolutions shares last traded at $12.08, with a volume of 1,263,793 shares.

Analyst Ratings Changes

Several brokerages recently issued reports on EBS. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Emergent Biosolutions presently has an average rating of “Hold” and a consensus price target of $15.00.

Emergent Biosolutions Price Performance

The firm has a market capitalization of $634.44 million, a PE ratio of 9.29 and a beta of 2.30. The firm’s fifty day moving average price is $11.74 and its 200 day moving average price is $9.65. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.18. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The company had revenue of $231.10 million during the quarter, compared to the consensus estimate of $203.67 million. As a group, equities analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Insider Transactions at Emergent Biosolutions

In other news, Director Ronald Richard sold 21,984 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total transaction of $263,148.48. Following the sale, the director owned 98,417 shares of the company’s stock, valued at $1,178,051.49. This trade represents a 18.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC boosted its stake in shares of Emergent Biosolutions by 143.0% during the 4th quarter. Palumbo Wealth Management LLC now owns 117,121 shares of the biopharmaceutical company’s stock worth $1,448,000 after acquiring an additional 68,925 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Emergent Biosolutions by 93.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,859 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 19,684 shares during the period. Baron Wealth Management LLC purchased a new position in Emergent Biosolutions during the fourth quarter worth approximately $133,000. SG Americas Securities LLC grew its holdings in Emergent Biosolutions by 164.5% in the fourth quarter. SG Americas Securities LLC now owns 40,529 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 25,207 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Emergent Biosolutions by 2.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 57,805 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 1,350 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.